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Objectives. Polymerized-type I collagen (polymerized collagen) is a downmodulator of inﬂammation and cartilage regenerator
biodrug. Aim. To evaluate the eﬀect of intraarticular injections of polymerized collagen after arthroscopic lavage on inﬂammation
and clinical improvement in patients with knee osteoarthritis (OA). Methods. Patients (n=19) were treated with 6 intraarticular
injections of 2mL of polymerized collagen (n = 10) or 2mL of placebo (n = 9) during 3 months. Followup was 3 months. The
primary endpoints included Lequesne index, pain on a visual analogue scale (VAS), WOMAC, analgesic usage, the number of
Tregs and proinﬂammatory/anti-inﬂammatory cytokine-expressing peripheral cells. Secondary outcomes were Likert score and
drug evaluation. Clinical and immunological improvement was determined if the decrease in pain exceeds 20mm on a VAS,
20% of clinical outcomes, and inﬂammatory parameters from baseline. Urinary levels of C-terminal crosslinking telopeptide of
collagen type II (CTXII) and erythrocyte sedimentation rate (ESR) were determined. Results. Polymerized collagen was safe and
well tolerated. Patients had a statistically signiﬁcant improvement (P<0.05) from baseline versus polymerized collagen and versus
placeboat6monthsonLequesneindex,VAS,ESR,TregsIL-1β,andIL-10peripheral-expressingcells.UrinarylevelsofCTXIIwere
decreased 44% in polymerized collagen versus placebo. No diﬀerences were found on incidence of adverse events between groups.
Conclusion. Polymerized collagen is safe and eﬀective on downregulation of inﬂammation in patients with knee OA.
1.Introduction
Osteoarthritis (OA), the most common form of arthritis, is
generally considered as a degenerative disorder. The inci-
dence of knee OA is high in the years following anterior
cruciate ligament or meniscal injury, and evidence suggests
that current arthroscopic procedures, including reconstruc-
tion of the anterior cruciate ligament and meniscectomy, are
not suﬃcient to restore normal joint mechanics or neutralize
the long-term risk of OA [1]. On the other hand, OA can be
viewed as an inﬂammatory disease characterized by progres-
sive deterioration of articular cartilage and synovial joints
[2–5]. Interleukin (IL)-1β, tumor necrosis factor (TNF)-α,
and IL-6 seem to be the main proinﬂammatory cytokines
involved in the pathophysiology of OA, even though others,
including IL-15, IL-18, IL-21, leukemia inhibitory factor2 The Scientiﬁc World Journal
(LIF), and chemokines have also been implicated [6]. Recent
progress has considerably improved knowledge of both the
factors involved in the development of OA and the mecha-
nisms responsible for its progression. Therefore, a new ther-
apeutic strategy is to develop drugs capable of modifying the
structural progression of OA (disease-modifying OA drugs
or DMOADs) in order to ameliorate the eﬀect of increasing
OA prevalence. DMOADs can cause retardation of disease
progression, a complete halt in disease progression, regen-
eration of cartilage, and even the prevention of disease de-
velopment. DMOADs in phase II/III clinical development
include oral salmon calcitonin, SD-6010, vitamin D3 (chole-
calciferol),collagenhydrolysate,recombinanthumanﬁbrob-
last growth factor (FGF)-18, bone morphogenetic protein
(BMP)-7, avocado-soybean unsaponiﬁable (ASU), and poly-
merized-typeIcollagen(ASPIDPHARMASAdeCV,Mexico
City, Mexico) [7–9].
Polymerized-type I collagen is a γ-irradiated mixture of
pepsinized porcine type I collagen and polyvinylpyrrolidone.
The addition of 1% polymerized-type I collagen to cartilage
and synovial tissue cocultures has shown to induce cartilage
regeneration owing to an increase of 3- to 6-fold chondro-
cytes proliferation (Ki-67) and cartilage extracellular matrix
proteins (proteoglycans, cartilage oligomeric matrix protein
or COMP, and type II collagen). Moreover, polymerized-
type I collagen induced downmodulation of inﬂammation
inhibiting proinﬂammatory cytokine expression (IL-1β and
TNF-α) and inducing upregulation of IL-10, an anti-in-
ﬂammatory cytokine. No diﬀerences were found on IL-8 or
TIMP-1 levels in supernatants from Polymerized-collagen-
treated cocultures when compared with untreated cultures.
Meanwhile IL-12 and IFN-γ were undetectable [8]. Intraar-
ticular (IA) administration of 2mL of polymerized type I to
knee OA patients showed a statistically signiﬁcant improve-
ment in Lequesne Index, WOMAC, pain intensity on a visual
analogue scale (VAS), patient global score, and analgesic
usage. This improvement was persistent during the followup
[9].
We consider that the administration of pharmacologic
agents at critical times, such as following injury and periop-
eratively might prevent disease development. For this reason,
the aim of the study was to evaluate the eﬀect of IA injec-
tions of polymerized collagen, on inﬂammation and clinical
improvement in patients with knee OA after arthroscopic
lavage.
2.MaterialsandMethods
2.1. Trial Design. This was a prospective, randomized, dou-
ble-blind, placebo controlled clinical trial.
2.2. Study Population
2.2.1. Inclusion Criteria. T h ep r o t o c o lw a sa p p r o v e db yt h e
IMSS Committee of Medical Ethics (Ref. no. 2800-758-053)
and was performed in accordance with the revised Decla-
ration of Helsinki, 1983. Only patients who gave written
informed consent to participate were recruited. Patients who
fulﬁlled the 1986 American College of Rheumatology for the
classiﬁcation of knee OA were included [10].
2.2.2. Exclusion Criteria. Patients who received oral, IA, or
parenteral corticosteroid use within 3 months, IA injection
of any hyaluronic substance into the knee within 90 days,
or operative arthroscopy within 5 months or treatment with
anticoagulants were excluded of the study. Patients with con-
current medical or arthritic conditions that could interfere
with evaluation of the index knee joint, including ﬁbromyal-
gia, Reiter’s syndrome, rheumatoid arthritis, psoriatic arthri-
tis, ankylosing spondylitis, lymphoma, arthritis associated
with inﬂammatory bowel disease, sarcoidosis, amyloidosis,
clinical signs and symptoms of active knee infection, crystal
disease, cancer, more signiﬁcant pain from the back or the
hip than the knee, patients with HIV or HCV, and patients
with drug or alcohol dependence history or sensitivity to
polymerized-type I collagen were also excluded.
2.3. Study Protocol. We calculated the sample size of 9 per
group. Patients were allocated using a random number gen-
eration and block randomization to two parallel groups [11].
Nineteen patients with a body mass index (BMI) ≤
40kgm−2, on stable therapy with NSAIDs and negative to
a standard forearm skin test to polymerized collagen admin-
istration(0.2mLofpolymerizedcollagenat72hoftheinitial
skin challenge) were enrolled in a 6-month study (1-week
run-inphase,12-weektreatmentphase,and3-monthfollow-
up phase). At baseline visit the eligibility of patients for the
study was conﬁrmed by review of history, clinical examina-
tion of the knee to be treated, and laboratory tests. Blood
was taken for hematology and clinical chemistry assessments
at baseline, 3, and 6 months. Patients were provided with
instructions on a set of standard physiotherapy exercises to
be performed throughout the study. Patients were instructed
in the daily use of a diary card on which it was recorded
compliance with standard physiotherapy and the use of any
additional analgesia or NSAIDs. Patients were also asked to
record adverse events (any unwanted event occurring during
the course of the trial whether if it was considered to be
related to administration of the study biodrug). At each
subsequent visit, eﬃcacy evaluations were conducted, and
adverse events and concomitant medications were recorded
prior to administration of study medication.
2.3.1. Arthroscopic Lavage. Arthroscopic lavage, with or
withoutdebridement,wasperformedinbothgroups.Brieﬂy,
skin around the knee was cleaned with a povidone-iodine
solution;thiswasfollowedbyaninjectionoflocalanesthetic,
into the outer mediopatellar zone. The anesthetic was al-
lowed to act, and an access way was then opened with num-
ber 6 abocat. The administration of the saline lavage was
preceded by drainage of any eﬀusion in the joint in order to
evacuate it as thoroughly as possible. Then, a volume around
100cm3 of cold saline was instilled through the outer access
way. Arthroscopic partial meniscectomy or loose body re-
mov-al was performed. Once the knee was distended, local
anesthetic was injected into the inner mediopatellar zone,
andanewabocatguidewasusedtoestablishtheinner drain-
age way, similarly to the outer one. The lavage proper in-
volved the instillation of 3L of cold (8◦C) saline at a constantThe Scientiﬁc World Journal 3
ﬂow rate by using a dropper line connected to the entry way;
the inner zone was also connected to another, free-fall drop-
per line that ended in a biological sample container. The per-
fusion time ranged from 90 to 120min, depending on the
individual characteristics of the patients. Once perfusion was
completed, any ﬂuid remaining in the joint was evacuated by
manually squeezing the distended joint cavity.
2.3.2. Intervention. After lavage, 2mL of polymerized colla-
gen (13.8mg of collagen) or 2mL of placebo (PVP citric/cit-
rate buﬀer) were administered into the joint under direct
ultrasound to ensure intraarticular injection. A compression
bandage was applied to the leg. It was removed by the patient
24h later. Six weeks after surgery patients received 5 IA in-
jections of 2mL of polymerized collagen or 2mL of placebo
(one per week) by either lateral or medial approach after the
instillation of 1mL of 1% xylocaine solution at weeks 8, 9,
10, 11, and 12 in the same knee that was selected by the
physician. The two experimental preparations were visually
identical, and its viscosity was very similar. Handling and
preparation of polymerized-type I collagenand placebo were
carried out by IMSS staﬀ in such a way as to maintain study
blinding, except that the study pharmacist was unblinded to
each participant’s study treatment. The institutional phar-
macists had access to a code list identifying whether the par-
ticipantreceivedpolymerized-typeIcollagenorplacebo.The
pharmacist did not disclose this information to any study
personnel. The participant study site personnel (other than
the research pharmacist) and patient were all blinded to the
treatment assignments. The rationale to inject IA polymer-
ized collagen was based on the previous experience related
to the biodrug eﬀects (anti-inﬂammatory and tissue regener-
ator eﬀects) observed during the course of the treatment of
k n e eO A[ 8, 9, 12–14].
2.4.ClinicalInterviewandOutcomes. Clinicalevaluationwas
performedatbaselineandeverymonthduringthestudy.The
primary endpoint included pain intensity on 10mm VAS
(patientandphysician),WOMACinstrument[15],Lequesne
index [16], and analgesic consumption. Secondary outcome
measures included patient’s and investigator’s global assess-
ment of disease activity on a 5-point rating scale, global
assessment of change in disease activity at the end of the
treatment (Likert score: 0 = very poor; 1 = poor; 2 = fair;
3 = well; 4 = very well) and patient’s and physician’s response
to therapy (evaluation of medication: 0 = none: no good at
all,ineﬀectivedrug;1 =poor:someeﬀect,butunsatisfactory;
2 = fair: reasonable eﬀect, but could be better; 3 = good:
satisfactory eﬀect with occasional episodes of pain or stiﬀ-
ness; 4 = excellent: ideal response, virtually pain-free) [17].
Clinically signiﬁcant improvement was determined if the
decrease in pain exceeds 20mm on the 0–100mm VAS [18]
and patients achieved at least 20% of improvement from
baseline in WOMAC [16, 18, 19] and Lequesne Index [17].
2.5. Safety Assessment. The safety of treatment was deter-
mined from the occurrence of systemic and local adverse
events. Adverse events and serious adverse events were as-
sessed by the investigator at each visit and followed until
resolution. Safety monitoring included records of vital signs
and clinical laboratory tests (blood chemistry, urinalysis and
liver function tests).
2.6. Laboratory Tests. Urinary levels of C-terminal cross-
linking telopeptide of collagen type II (CTXII) were assessed
byaone-stepsandwichenzymeimmunoassay(ELISA)(Urine
CartiLaps EIA, Immunodiagnostic Systems Inc, Arizona,
USA).TheCTX-IIvalueswerecorrectedwithcreatininecon-
centration (μgmmol−1) and perform the correction using
the equation: corrected CTX-II value (ngmmol−1) = 1000 ×
Urine CartiLaps (μgL −1)/creatinine (mmolL−1)[ 19]. Ery-
throcyte sedimentation rate (ESR) was determined by West-
ergren method. Anticyclic citrullinated peptide (anti-CCP3)
IgGantibodiesweredeterminedwithacommercialELISAkit
(INOVA, San Diego, CA). Assay was performed according to
the manufacturer’s instructions.
2.7. Peripheral Blood Mononuclear Cells (PBMCs) Isolation.
A 10mL sample of venous blood was obtained from each
subject under polymerized collagen or placebo treatment at
baseline, 3, and 6 months of the study. Thirteen healthy age-
matched subjects without overweight (in order to avoid sys-
temic inﬂammation associated with body fat) who volun-
teered were included as controls. PBMCs were obtained by
gradient centrifugation on Lymphoprep (Axis-Shield PoC
AS, Oslo, Norway).
2.8. Flow Cytometry. PBMCs (1×106) were stained with 5μL
of anti-CD4-PECy5-labelled, anti-CD14-FITC-labelled, anti-
CD8-PECy5-labelled, and anti-CD28-FITC-labelled mono-
clonal antibodies (BD Biosciences, San Jose, CA) at room
temperature in the dark for 20min. After two washes, PBMC
werepermeabilizedwith200μLofcytoﬁx/cytopermsolution
(BD Biosciences) at 4◦C for 20min. PBMCs were stained
for intracellular cytokines and transcription factors with
anti-IL-1β-PE-labelled, anti-TNF-α-PE-labeled, anti-IL-10-
PE-labelled, anti-IFN-γ-PE-labeled (BD Biosciences), and
PE-labelled-anti-Foxp3 for Tregs (eBioscience) monoclonal
antibodies, for 30min at 4◦C in the dark. Finally, after wash-
ing, PBMCs subsets were analyzed by ﬂow cytometry with
a FACScan (BD Biosciences). An electronic gate was made
for CD4+/CD14−,C D 4 −/CD14+, CD8+/CD28−, or CD8+
cells, and a total of 50000 events were recorded for each sam-
ple and analyzed with the CellQuest software (BD Bioscien-
ces). Results are expressed as the relative percentage of IL-1β,
TNF-α, IL-10, IFN-γ, or Foxp3-expressing cells in each
gate. As isotype controls, IgG1-FITC/IgG1-PE/CD45-PeCy5
mouse IgG1k (BD Tritest, BD Biosciences) were used to set
the threshold and gates in the cytometer.
In order to avoid false positive PE results and also for set-
ting compensation for multicolor ﬂow cytometric analysis,
weperformedinstrumentcalibration/standardizationproce-
dures each day according to established protocols of our lab-
oratory. Brieﬂy, we run an unstained (autoﬂuorescence con-
trol) and permeabilized PBMCs sample. Autoﬂuorescence
control (unstained cells) was compared with single stained
cell positive controls to conﬁrm that the stained cells were on
scale for each parameter. Besides, BD Calibrite 3 beads were4 The Scientiﬁc World Journal
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Figure 1: Primary and secondary measures of eﬃcacy. Clinical evaluation was performed at baseline and every month during the study.
The primary endpoints included (a) Lequesne index, (b) patient pain visual analogue scale (VAS), (c) physician pain visual analogue scale
(VAS), (d) WOMAC pain subscale, (e) WOMAC stiﬀness subscale, (f) WOMAC disability subscale, (g) patient’s and (h) physician’s global
assessment of disease activity on a 5-point rating scale, global assessment of change in disease activity at the end of the treatment (Likert
score: 0 = very poor; 1 = poor; 2 = fair; 3 = well; 4 = very well), (i) consumption of NSAIDs tablets per month. Arrows depict the month
in which the treatment reached a P<0.05 compared to baseline, in black for placebo and in red for polymerized collagen group. Results
represent mean ± SD. P values indicate statistical signiﬁcant diﬀerences between treatment groups.
used to adjust instrument settings, set ﬂuorescence compen-
sation, and check instrument sensitivity (BD CaliBRITE, BD
Biosciences).
2.9. Statistical Analysis. We calculated the sample size with
a formula for calculating sample for proportion: N =
[
√
{pq(1 + 1/k)}z1 − α/2+
√
{p1q1 + p2q2/k}z1−β]
2/Δ2.W e
considered a 20% dropout rate. For the primary analysis, the
means of the scores were compared between the two treat-
ment groups on an intention to treat (ITT) basis (all patients
who received a dose of study medication and had at least
one eﬃcacy observation recorded after treatment). StatisticalThe Scientiﬁc World Journal 5
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Figure 2: Percentage of CD14-derived proinﬂammatory cytokine in OA knee patients. (a) An electronic gate was made for CD4−/CD14+
single positive cells. (b) From the gate a CD4−/CD14+/IL-1β+ cells were determined. (c) Percentage of CD4−/CD14+/IL-1β+ peripheral
blood cells was established at baseline, 3, and 6 months. (d) An electronic gate was made for CD4−/CD14+ single positive cells. (e) From
the gate d CD4−/CD14+/TNF-α+ cells were determined. (f) Percentage of CD4−/CD14+/TNF-α+ peripheral blood cells was established at
baseline, 3, and 6 months. (g) An electronic gate was made for CD4−/CD14+ single positive cells. (h) From the gate f CD4−/CD14+/IL-
10+ cells were determined. (i) Percentage of CD4−/CD14+/IL-10+ peripheral blood cells was established at baseline, 3 and 6 months. (j)
An electronic gate was made for CD4+/CD14− single positive cells. (k) From the gate j CD4+/CD14−/Foxp3+ cells were determined. (l)
Percentage of CD4+/CD14−/Foxp3+ peripheral blood cells was established at baseline, 3, and 6 months. (m) An electronic gate was made
for CD8+/CD28− single positive cells. (n) From the gate m CD8+/CD28−/Foxp3+ cells were determined. (o) Percentage of CD8+/CD28−/
Foxp3+ peripheral blood cells was established at baseline, 3, and 6 months. The software employed was CellQuest (BD Biosciences). A total
of 50,000 events were recorded for each sample. Results are expressed as mean ± SE. ∗P<0.05.
Table 1: Demographic characteristics of the patients.
Healthy control (n = 13) Placebo (n = 9) Polymerized-type I collagen (n = 10)
Baseline Baseline
Age (years); Mean ± SD 42.0 ± 8.1 57.0 ± 8.1 59.9 ± 9.7
Median 42.0 53.0 56.5
Range (40.0–54.0) (50.0–74.0) (50.0–75.0)
Gender (female/male) 11/2 6/3 8/2
Disease duration (years); mean ± SD 6.4 ± 3.4 4.0 ± 3.5
Median 5.0 2.0
Range (3.0–11.0) (0.7–10.0)
OA grade (n) III (1) III (3)
IV (8) IV (7)
Body mass index (kgm−2); mean ± SD 21.5 ± 1.6 30.7 ± 6.3 28.4 ± 3.9
Median 21.4 27.9 28.8
Range (18.9–24.2) (26.9–40.0) (20.4–32.9)
analysis was performed using the SigmaStat11 program by
One Way Analysis of Variance on Ranks and by Holm-Sidak
method for all pairwise multiple comparison procedures.
Datawereexpressedasthemean±SD.Valuessmallerthanor
equal to 0.05 were considered as signiﬁcant.
3. Results
Nineteen patients who met criteria for inclusion into the
study were randomized to polymerized collagen (n = 10) or
placebo (n = 9) treatments; all patients completed the study.
3.1. Patient Demographics and Baseline Disease Characteris-
tics. Sixty seven per cent in placebo and 80% in polymerized
collagen group were females. The two treatment groups were
similar with respect to age, disease duration, and BMI, with
no statistical diﬀerences (Table 1).
3.2. Primary Clinical Outcomes. Scores decreased at statisti-
cally signiﬁcant levels from baseline to 3 months (treatment
phase) and 6 months (followup) for patients under Polymer-
ized-type I collagen treatment compared with patients un-
der placebo treatment (Table 2, Figure 1), in Lequesne IndexThe Scientiﬁc World Journal 7
Table 2: Clinical characteristics of the patients.
Placebo (n = 9) Polymerized-type I
collagen (n = 10)
Baseline 3 months 6 months Baseline 3 months 6 months
Patient pain (mm); mean ± SD 7.5 ± 1.2 4.8 ± 3.1 5.5 ± 2.3 7.2 ± 2.3 2.6 ± 2.5 2.7 ± 2.3
Median 8.0 4.0 5.5 8.0 1.7 2.0
Range (6.0–9.0) (1.0–9.0) (1.0–8.5) (4.0–10.0) (0.5–7.8) (0.0–6.5)
Physician pain (mm); mean ± SD 7.6 ± 1.5 3.4 ± 3.0 5.1 ± 2.3 7.6 ± 1.8 2.7 ± 2.9 2.8 ± 2.1
Median 8.0 2.0 4.8 8.0 1.9 2.0
Range (5.5–9.0) (1.0–9.1) (1.0–8.0) (4.0–10.0) (0.0–8.0) (0.0–6.0)
Lequesne; mean ± SD 13.1 ± 3.0 11.6 ± 4.0 12.9 ± 3.3 12.8 ± 2.7 7.3 ± 1.9 6.2 ± 3.6
Median 14.0 11.0 13.0 13.0 7.5 7.0
Range (8.0–18.0) (6.0–19.0) (9.0–19.0) (8.0–16.0) (4.0–10.0) (1.0–12.0)
WOMAC pain subscale; mean ± SD 11.2 ± 3.6 7.1 ± 3.7 8.2 ± 3.9 11.1 ± 4.1 5.8 ± 2.8 4.0 ± 3.0
Median 10.0 7.0 8.0 10.5 4.5 3.0
Range (6.0–19.0) (1.0–12.0) (3.0–15.0) (7.0–19.0) (3.0–11.0) (0.0–8.0)
WOMAC stiﬀness subscale; mean ± SD 3.9 ± 1.9 3.2 ± 2.0 3.7 ± 2.0 3.6 ± 2.6 2.4 ± 1.9 1.9 ± 1.7
Median 4.0 2.0 5.0 3.5 2.0 2.0
Range (0.0–7.0) (0.0–6.0) (0.0–6.0) (1.0–8.0) (0.0–6.0) (0.0–4.0)
WOMAC disability subscale; mean ± SD 37.1 ± 15.6 26.3 ± 17.2 26.4 ± 14.7 41.0 ± 14.2 19.0 ± 12.6 15.2 ± 11.6
Median 43.0 22.0 26.0 37.0 20.5 21.0
Range (11.0–56.0) (2.0–58.0) (6.0–50.0) (27.0–68.0) (4.0–35.0) (0.0–33.0)
Patient Likert score (cm); mean ± SD 1.1 ± 0.8 2.1 ± 1.1 2.1 ± 0.9 1.2 ± 0.6 2.8 ± 0.9 2.7 ± 0.7
Median 1.0 2.0 2.0 1.0 3.0 3.0
Range (0.0–2.0) (1.0–4.0) (1.0–3.0) (0.0–2.0) (1.0–4.0) (2.0–4.0)
Physician Likert score (cm); mean ± SD 1.0 ± 0.8 2.3 ± 1.0 2.5 ± 0.9 1.5 ± 0.7 3.1 ± 0.4 3.1 ± 0.6
Median 1.0 2.0 2.5 2.0 3.0 3.0
Range (0.0–2.0) (1.0–4.0) (1.0–4.0) (0.0–2.0) (3.0–4.0) (2.0–4.0)
Patient drug evaluation (cm); mean ± SD 2.4 ± 1.0 2.1 ± 0.8 2.9 ± 0.6 3.1 ± 0.6
Median 3.0 2.0 3.0 3.0
Range (1.0–4.0) (1.0–3.0) (2.0–4.0) (2.0–4.0)
Physician drug evaluation (cm); mean ± SD 2.1 ± 1.4 2.3 ± 1.0 2.9 ± 0.4 3.1 ± 0.6
Median 2.0 2.5 3.0 3.0
Range (0.0–4.0) (0.0–3.0) (2.0–3.0) (2.0–4.0)
Analgesic usage (tablets day−1); mean ± SD 40.4 ± 17.1 53.3 ± 20.0 71.1 ± 38.6 40.4 ± 17.1 13.0 ± 10.9 7.0 ± 4.9
Median 30.0 60.0 60.0 30.0 12.0 7.0
Range (16.0–60.0) (30.0–90.0) (30.0–150.0) (16.0–60.0) (0.0–30.0) (0.0–14.0)
(≈−43% and ≈−51% at treatment phase and followup;
Figure 1(a)), WOMAC pain subscale ≈−51% at 6 months;
Figure 1(d)), WOMAC stiﬀness subscale ≈−49% at 6
months; Figure 1(e)), WOMAC disability subscale (≈−28%,
and ≈−42% at 3 and 6 months; Figure 1(f)), patient pain on
aVAS(≈−46%,and≈−51%at3and6months;Figure 1(b)),
and physician pain on a VAS (≈−21%, and ≈−45% at 3 and
6 months; Figure 1(c)) improving substantially more than
the prespeciﬁed eﬀect size (20%) in patients who received
polymerized collagen versus placebo (Table 2).
3.3. Secondary Measures of Eﬃcacy. Scores improved consid-
erably for patient and physician from baseline to 3 months
(treatment phase) and 6 months (followup) for both active
and placebo treatment (Table 2, Figure 1). There was a
signiﬁcant diﬀerence (P<0.05) between treatments for pa-
tient’s Likert score (≈33% and ≈28%, at 3 and 6 months;
Figure 1(g)), physician’s Likert score (≈35% and ≈24%, at 3
and 6 months; Figure 1(h)), patient drug evaluation (≈21%
and ≈48%, at 3 and 6 months), and physician drug evalua-
tion (≈38% and ≈35%, at 3 and 6 months).
3.4. Concomitant Medication. The placebo-treated group
increased76percentconsumptionofNSAIDstabletsperday
(P = 0.01; Table 2, Figure 1(i)). Meanwhile, Polymerized-
type I collagen-treated group decreased 83 per cent NSAIDs
tablets per day (P = 0.016; compared baseline to ﬁnal eval-
uation; Table 2, Figure 1(i) and P< 0.001 between treat-
ments).8 The Scientiﬁc World Journal
Table 3: Laboratory characteristics of the patients.
Placebo (n = 9) Polymerized-type I
collagen (n = 10)
Baseline 3 months 6 months Baseline 3 months 6 months
Erythrocyte sedimentation rate (mmHg)
Mean ± SD 15.5 ± 10.1 19.6 ± 12.9 12.8 ± 10.6 15.5 ± 10.1 11.9 ± 13.1 7.8 ± 6.7
Anti-cyclic citrullinated peptide
antibodies (U); mean ± SD 1.8 ± 0.7 4.3 ± 4.8
Median 1.9 2.7
Range (0.9–3.0) (0.5–13.4)
Urinary levels of C-terminal crosslinking
telopeptide of collagen type II
(ngmmol−1); mean ± SD
281.4 ± 291.5 283.1 ± 245.0 474.4 ± 333.9 214.3 ± 179.9 196.6 ± 167.4 266.6 ± 146.7
Median 160.0 229.3 460.4 171.9 158.9 237.4
Range (60.1–882.8) (102.1–896.2) (64.6–986.0) (6.9–592.3) (0.1–505.9) (91.7–472.0)
3.5. Adverse Events. The most frequent adverse event was in-
jection site pain lasting <24h. No patient developed aseptic
acute arthritis (chemical reaction) within 24 and 72 hours
after IA injection.
3.6. Laboratory Assessment. There were no changes in com-
plete blood counts, measurement of liver function test, and
urinalysis. Urinary CTX-II was determined as a marker of
cartilage degradation. A 1.4–1.7-fold increase of CTX-II was
quantiﬁed in placebo group compared with polymerized
collagen group (≈−31% and ≈−44%, at 3 and 6 months;
Table 3). There was a statistical diﬀerence in ESR between
placebo and polymerized collagen treatment (≈−39% and
≈−40%, at 3 and 6 months; Table 3, P<0.05).
3.7.ProinﬂammatoryCytokineExpressioninTCD8Peripheral
Cells. Results show that the amounts of CD8+/IL-1β+-,
CD8+/TNF-α+-, and CD8+/IFN-γ+-expressing peripheral
cells were lower in patients under polymerized-type I colla-
gentreatmentcomparedwithplaceboat3and6months(IL-
1β: ≈−44%and ≈−53%;TNF-α: ≈−33%and ≈−47%;IFN-
γ: ≈−34% and ≈−12%; Table 4).
3.8. Proinﬂammatory and Anti-Inﬂammatory Cytokine Ex-
pressioninTCD4PeripheralCells. ThepercentagesofCD4+/
CD14−/IL-1β+- and CD4+/CD14−/TNF-α+-expressing pe-
ripheral cells were lower in patients under polymerized-type
I collagen treatment versus placebo at 3 and 6 months under
treatment (IL-1β: ≈−69% and ≈−31%; TNF-α: ≈−48% at 6
months; Table 4). CD4+/CD14−/IL-10+-producing cells, an
anti-inﬂammatory cytokine, were higher in patients un-
der polymerized collagen treatment versus placebo-treated
group at 3 and 6 months (≈92% and ≈32%; Table 4).
3.9. Proinﬂammatory and Anti-Inﬂammatory Cytokine Ex-
pression in CD14 Monocytes Peripheral Cells. Results show
that the amounts of CD4−/CD14+/IL-1β+- and CD4−/
CD14+/TNF-α+-expressing peripheral cells were lower in
patients under polymerized-type I collagen treatment com-
pared with placebo at 3 and 6 months (IL-1β: ≈−10% and
≈−61%, Figures 2(a)–2(c);T N F - α: ≈−52% and ≈−38%;
Figures 2(d)–2(f), Table 4).
CD4+/CD14−/IL-10+-producing cells were conspicu-
ously higher in patients under polymerized collagen versus
placebo-treated group at 3 and 6 months (≈18% and
≈300%; Figures 2(g)–2(i), Table 4).
3.10. Regulatory T Peripheral Cells. Polymerized-type I col-
lagen induced a statistically signiﬁcant increase in Foxp3+-
expressingCD4+/CD14−andCD8+/CD28−peripheralcells
compared to patients under placebo treatment at 3 and 6
months (CD4: ≈14% and ≈65%, P<0.027; Figures 2(j)–
2(l), CD8: ≈60%, P<0.03 and ≈38%; Figures 2(m)–2(o),
Table 4).
4. Discussion
OAisthemostcommonformofarthritisandaleadingcause
of disability; however, there is a large unmet need for desira-
ble pharmacologic therapeutic interventions. This pathology
oﬀers a key research and development opportunity in terms
of scientiﬁc innovation, medical requirement, and market
size. The current pharmacologic agents have not been shown
to have convincing disease-modifying eﬃcacy. In this vein,
combination of treatments could oﬀer innovative therapeu-
tic possibilities. Hence, to optimize pharmacological treat-
ment in patients with OA, it is also necessary to assist in
preserving joint integrity through arthroscopic procedures.
In this study, we determined clinical eﬃcacy of perioper-
atively IA injections of polymerized collagen in symptomatic
knee OA patients compared with baseline and placebo at 3
months. Clinical improvement and elevated response rates
were found in primary outcomes including Lequesne In-
dex, WOMAC pain subscale, WOMAC stiﬀness subscale,
WOMAC disability subscale, and patient’ and physician’ VAS
pain. Response to treatment was sustained until followup.
In addition we determined improvement in secondary end-
points.WealsofoundincreasedlevelsofurinaryCTX-IIonly
in patients treated with placebo, indicating the progression
of joint damage. It is noteworthy that, patients who re-
ceived polymerized collagen decreased noticeably NSAIDsThe Scientiﬁc World Journal 9
Table 4: PBMCs proinﬂammatory, anti-inﬂammatory cytokine production and Foxp3-expressing T cells.
Healthy controls
(n = 13)
Placebo (n = 9) Polymerized-type I
collagen (n = 10)
Baseline 3 months 6 months 3 months 6 months
CD4+/CD14−/IL-1β+(%); mean ± SD 1.1 ± 0.3 1.8 ± 0.3 3.5 ± 1.9 2.6 ± 0.6 1.1 ± 0.2 1.8 ± 0.4
Median 0.9 1.3 2.0 2.1 1.1 1.5
Range (0.0–3.4) (0.2–4.8) (1.0–14.5) (1.6–6.7) (0.1–2.0) (1.0–4.2)
CD4−/CD14+/IL-1β+(%); mean ± SD 3.97 ± 0.7 4.9 ± 1.5 4.8 ± 1.3 8.5 ± 2.4 5.3 ± 1.0 3.3 ± 0.6∗
Median 3.7 2.4 3.9 6.9 5.8 3.1
Range (0.8–8.0) (0.2–18.1) (0.8–12.8) (1.5–18.7) (0.6–8.1) (0.8–6.1)
CD4+/CD14+/IL-1β+(%); mean ± SD 0.9 ± 0.3 0.8 ± 0.4 1.0 ± 0.3 2.9 ± 2.0 1.1 ± 0.4 1.0 ± 0.3
Median 0.8 0.7 0.6 2.1 0.7 0.8
Range (0.1–2.1) (0.1–3.7) (0.3–2.5) (1.0–6.6) (0.2–3.7) (0.1–2.5)
CD4+/CD14−/TNF-α+(%); mean ± SD 0.6 ± 0.1 1.7 ± 0.4 1.3 ± 0.4 2.3 ± 0.6 2.2 ± 0.7 1.2 ± 0.3
Median 0.6 1.5 1.0 1.5 1.5 1.3
Range (0.0–1.9) (0.2–4.5) (0.2–2.7) (0.9–5.6) (0.5–5.5) (0.3–2.7)
CD4−/CD14+/TNF-α+(%); mean ± SD 3.8 ± 0.7 4.7 ± 1.2 7.5 ± 2.3 5.6 ± 1.2 3.6 ± 0.9 3.5 ± 0.8
Median 4.1 2.4 6.9 5.3 3.4 2.7
Range (0.6–9.5) (0.2–17.2) (0.3–17.2) (1.4–9.7) (0.7–7.2) (0.7–8.1)
CD4+/CD14+/TNF-α+(%); mean ± SD 0.8 ± 0.2 0.7 ± 0.2 1.1 ± 0.6 1.2 ± 0.2 1.5 ± 0.5 0.9 ± 0.2
Median 0.7 0.5 0.3 1.1 1.3 1.0
Range (0.1–2.1) (0.1–2.5) (0.2–4.6) (0.4–2.1) (0.3–3.7) (0.1–2.0)
CD4+/CD14−/IL-10+(%); mean ± SD 2.3 ± 0.9 2.4 ± 0.5 1.4 ± 0.4 1.9 ± 0.5 2.7 ± 0.9 2.5 ± 0.5
Median 2.3 1.5 0.9 1.4 1.5 2.5
Range (0.2–4.6) (0.3–7.1) (0.2–3.0) (0.2–3.8) (0.2–7.6) (0.4–4.5)
CD4−/CD14+/IL-10+(%); mean ± SD 9.2 ± 1.1 5.0 ± 1.3 3.3 ± 0.8 3.8 ± 0.9 3.9 ± 1.1 15.2 ± 3.3∗
Median 8.9 2.4 3.5 3.9 3.5 14.7
Range (3.2–10.2) (0.2–19.4) (0.3–6.1) (0.7–7.5) (0.8–10.2) (4.0–30.3)
CD4+/CD14+/IL-10+(%); mean ± SD 1.2 ± 0.3 0.9 ± 0.4 0.6 ± 0.2 1.0 ± 0.3 0.5 ± 0.1 1.2 ± 0.1
Median 1.1 0.4 0.5 0.6 0.4 1.2
Range (0.2–1.6) (0.1–6.7) (0.0–1.6) (0.1–2.6) (0.1–0.8) (0.5–1.7)
CD4+/CD14−/Foxp3+(%); mean ± SD 3.8 ± 0.5 2.5 ± 0.8 2.2 ± 0.5 2.0 ± 0.3 2.5 ± 0.6 3.3 ± 0.3∗
Median 3.5 1.5 2.0 2.0 1.9 3.1
Range (2.1–8.8) (0.1–14.2) (0.5–4.3) (0.8–3.2) (1.1–5.6) (2.2–4.7)
CD8+/IL-1β+(%); mean ± SD 3.1 ± 1.1 2.5 ± 0.8 4.9 ± 1.5 1.4 ± 0.4 2.3 ± 0.5
Median 1.0 1.7 3.6 1.3 2.4
Range (0.2–15.0) (0.7–8.4) (1.6–14.5) (0.1–3.0) (0.7–4.5)
CD8+/TNF-α+(%); mean ± SD 2.9 ± 0.7 2.1 ± 0.8 3.4 ± 1.5 1.4 ± 0.3 1.8 ± 0.4
Median 1.9 0.8 0.8 1.2 1.5
Range (0.2–11.8) (0.0–7.6) (0.2–11.3) (0.1–2.7) (0.6–3.5)
CD8+/IFN-γ+(%); mean ± SD 7.4 ± 1.5 6.7 ± 1.6 3.7 ± 0.6 4.4 ± 0.9 3.3 ± 0.7
Median 4.6 5.6 3.0 3.8 3.0
Range (0.5–18.8) (1.2–17.4) (2.2–6.8) (0.8–8.1) (1.1–6.9)
CD8+/CD28−/Foxp3+(%); mean ± SD 2.9 ± 0.6 6.9 ± 1.3 4.3 ± 0.8 4.7 ± 1.0 6.9 ± 1.1∗ 6.5 ± 1.0
Median 3.1 4.0 4.5 3.9 6.9 6.4
Range (0.2–6.2) (0.5–18.0) (1.3–9.3) (1.3–9.9) (2.4–9.6) (3.1–11.4)10 The Scientiﬁc World Journal
consumption at statistically signiﬁcant levels compared with
baseline and placebo group. None of the patients have re-
quired joint replacement as of today. This clinical outcome
was reached 3 to 5 months before that reported in previous
polymerized collagen study [9]. This suggests that poly-
merized-collagen administration, after arthroscopic lavage,
could improve time to response to pharmacologic therapeu-
tics. Arthroscopic surgery removed not only particulate
material,suchascartilagefragmentsandcalciumcrystalsbut
also soluble proteins such as proinﬂammatory cytokines and
proteolytic enzymes. On the other hand polymerized colla-
gen downregulated pro-inﬂammatory cytokine production
and decreased synovitis, improving motion.
However, our study has a number of limitations includ-
ing the lack of X-ray analysis to determine the progression of
joint space narrowing and the high rate of response to place-
bo. Elevated response rates to placebo have been reported in
o t h e rO At r i a l s[ 20–22] and may be related, at least in part,
to patients’ biases and expectations and to placebo adminis-
tration per se. A similar clinical improvement in WOMAC,
Patient Global Assessment, Investigator Global Assessments,
andPaincomparedtosaline(control)injectionswasalsoob-
served in previous studies with the three-injection regimen
of high molecular weight hyaluronan (Orthovisc) or arthro-
centesis as the control [21, 22]. The most common and sig-
niﬁcant adverse events were limited to acute local reactions.
Earlier studies have shown that OA is an inﬂammatory
disease [3–5]. Immunohistochemical studies have conﬁrmed
that synovial tissue from patients with early OA is character-
ized by mononuclear cell inﬁltration, production of pro-
inﬂammatory cytokines, and mediators of joint damage.
Mechanisms by which synovitis exacerbates structural dam-
ageinOAarelikelytobecomplex.Hypotheseshaveincluded
alterations in chondrocyte function, enhanced angiogenesis,
changes in bone turnover, and inﬂammation. Excessive pro-
duction of IL-1β,T N F - α, IL-8, and IL-6 by synovial tissue
and cartilage can stimulate, in either autocrine or paracrine
manner, chondrocytes to produce MMPs and plasminogen
activator, which in turn degrade matrix proteoglycans and
collagens and subchondral bone [3–8]. Besides, systemic
markers of inﬂammation such as C-reactive protein (CRP),
MMP-7, IL-15, plasminogen activator inhibitor (PAI)-1, and
soluble vascular adhesion protein (sVAP)-1 are upregulated
in OA as compared to controls, although to a lesser extent
than that observed in RA [18, 23]. Polymerized collagen has
been shown to have immunomodulatory eﬀects on several
pathologies associated with chronic inﬂammatory processes
[8, 9, 24–27]. Hence, Polymerized collagen could be involved
in downregulation of peripheral blood proinﬂammatory
cytokine-expressing cells contributing to decrease cell acti-
vation and avoiding circulating cell migration into inﬂamed
tissue in order to downmodulate in situ inﬂammation.
Further, polymerized collagen has been shown to have a
regenerator eﬀect in experimental induction of heterotopic
bone and scleroderma skin lesions [13, 28]. Our ﬁndings are
in agreement with those studies, for patients under treat-
ment with polymerized-type I collagen who showed lower
percentage of IL-1β-a n dT N F - α-producing peripheral cells
and higher number of IL-10- and Foxp3-expressing cells
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Figure 3: Total cytokine- and Foxp3-expressing peripheral cells
in patients with symptomatic knee OA under Polymerized-type I
collagen or placebo at baseline, 3, and 6 months.
compared with placebo-treated group. This suggests that the
inﬂammatory process could be modiﬁed due to downregu-
lation of IL-1β and TNF-α production which is probably a
consequence of increased IL-10 levels and higher number of
Treg cells (Figure 3).
Summing up, our results indicate that administration of
polymerized type I collagen after arthroscopic lavage has an
excellent safety and eﬃcacy proﬁle, highlighted by a low rate
of injection site reactions. In addition, polymerized collagen
induces systemic downregulation of inﬂammation. Certain-
ly, continuing research is required to establish the potential
eﬃcacy and to increase our understanding of the biology,
pharmacology, and pharmacokinetics of this biodrug.
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